Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma

被引：0
|
作者：
Parrondo, Ricardo D. [1 ]
Laplant, Betsy R. [2 ]
Elliott, Jamie [1 ]
Fernandez, Andre [1 ]
Flott, Caitlin J. [1 ]
Arrington, Diedre [1 ]
Chapin, Dustin [1 ]
Brown, Jade [1 ]
Das, Saurav [1 ]
Roy, Vivek [1 ]
Chanan-Khan, Asher A. [1 ,3 ]
Ailawadhi, Sikander [1 ,3 ]
机构：
[1] Mayo Clin, Canc Ctr, Dept Hematol Oncol, Jacksonville, FL 32224 USA
[2] Mayo Clin, Quantitat Hlth Sci, Rochester, MN USA
[3] Mayo Clin, Ctr Canc, Dept Canc Biol, Jacksonville, FL 32224 USA
来源：
BLOOD CANCER JOURNAL | 2024年 / 14卷 / 01期
关键词：
D O I：
10.1038/s41408-024-01134-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Daratumumab-resistant multiple myeloma with extramedullary disease successfully treated with combination elotuzumab, pomalidomide and dexamethasone: A case report
    Sakashita, Masataka
    Sahara, Naohi
    Aoki, Jun
    Matsunaga, Takashi
    Kobayashi, Seiichiro
    Kitahara, Shinsuke
    Fujii, Tomoki
    Ohno, Nobuhiro
    ONCOLOGY LETTERS, 2024, 27 (06)
  • [42] CheckMate 602: An open-label, randomized, phase 3 trial of combinations of nivolumab, elotuzumab, pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.
    Lonial, Sagar
    Richardson, Paul G.
    Reece, Donna Ellen
    Mohamed, Hesham
    Shelat, Suresh
    Miguel, Jesus San
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [43] A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma
    Van Oekelen, Oliver
    Parekh, Samir
    Cho, Hearn J.
    Vishnuvardhan, Nivetha
    Madduri, Deepu
    Richter, Joshua
    Ip, Chun
    Lau, Kenneth
    Florendo, Erika
    Mancia, Ines S.
    Thomas, Joanne
    Verina, Daniel
    Chan, Elaine
    Zarychta, Katarzyna
    La, Lisa
    Strumolo, Gina
    Melnekoff, David T.
    Leshchenko, Violetta V.
    Kim-Schulze, Seunghee
    Couto, Suzana
    Wang, Maria
    Pierceall, William E.
    Thakurta, Anjan
    Lagana, Alessandro
    Jagannath, Sundar
    Chari, Ajai
    LEUKEMIA & LYMPHOMA, 2020, 61 (09) : 2208 - 2215
  • [44] CheckMate 602: A Phase 3, Open-Label, Randomized Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide, and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
    Lonial, Sagar
    Richardson, Paul
    Reece, Donna
    Mohamed, Hesham
    Shelat, Suresh
    San Miguel, Jesus
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S330 - S330
  • [45] Dedalo: Phase II Study of Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Patients with Relapsed/ Refractory Multiple Myeloma and 17p Deletion
    Montefusco, Vittorio
    Cafro, Anna Maria
    Casaluci, Gloria Margiotta
    Patriarca, Francesca
    Mina, Roberto
    D'Agostino, Mattia
    Capra, Andrea
    Priola, Claudia
    Dalla Palma, Anna Benedetta
    Rizzi, Rita
    Genua, Angelo
    Petrucci, Maria Teresa
    Paris, Laura
    Belotti, Angelo
    Cavo, Michele
    Conticello, Concetta
    Carlo-Stella, Carmelo
    Boccadoro, Mario
    BLOOD, 2022, 140 : 10193 - 10195
  • [46] MonumenTAL-3: Phase 3 Trial of Talquetamab plus Daratumumab ± Pomalidomide Versus Daratumumab plus Pomalidomide plus Dexamethasone in Relapsed/Refractory Multiple Myeloma Following ≥1 Prior Line of Therapy
    Cohen, Yael C.
    Moreau, Philippe
    Tolbert, Jaszianne
    Qin, Xiang
    Ma, Xuewen
    Vieyra, Diego
    Langlois, Angelique
    Courtoux, Christelle
    Terry, William
    Pei, Lixia
    Heuck, Christoph
    Voorhees, Peter
    BLOOD, 2022, 140 : 4418 - 4419
  • [47] Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
    Yarlagadda, Lakshmi
    Gundarlapalli, Sravani
    Parikh, Richa
    Landes, Reid D.
    Kottarathara, Mathew
    Ogunsesan, Yetunde
    Hoque, Shadiqul
    Mitma, Angel A.
    Bailey, Clyde
    Hill, Kerri M.
    Thanendrarajan, Sharmilan
    Graziutti, Monica
    Mohan, Meera
    Zangari, Maurizio
    van Rhee, Frits
    Tricot, Guido
    Schinke, Carolina
    CANCERS, 2021, 13 (16)
  • [48] Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial
    Dimopoulos, Meletios A.
    Terpos, Evangelos
    Boccadoro, Mario
    Delimpasi, Sosana
    Beksac, Meral
    Katodritou, Eirini
    Moreau, Philippe
    Baldini, Luca
    Symeonidis, Argiris
    Bila, Jelena
    Oriol, Albert
    Mateos, Maria-Victoria
    Einsele, Hermann
    Orfanidis, Ioannis
    Ahmadi, Tahamtan
    Ukropec, Jon
    Kampfenkel, Tobias
    Schecter, Jordan M.
    Qiu, Yanping
    Amin, Himal
    Vermeulen, Jessica
    Carson, Robin
    Sonneveld, Pieter
    LANCET ONCOLOGY, 2021, 22 (06): : 801 - 812
  • [49] Daratumumab, pomalidomide, and dexamethasone in relapsed refractory multiple myeloma (RRMM): A comparison with contemporary clinical trials.
    Paul, Barry
    Robinson, Myra M.
    Robinson, Jordan
    Ndiaye, Ami
    Bhutani, Manisha
    Voorhees, Peter Michael
    Symanowski, James Thomas
    Friend, Reed N.
    Pineda-Roman, Mauricio
    Usmani, Saad Zafar
    Atrash, Shebli
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [50] Elotuzumab in combination with pomalidomide and dexamethasone (EloPd) in relapsed refractory multiple myeloma (RRMM): a network meta-analysis
    Farrell, James
    Bertin, Nicolas
    Fischer, Claire
    Gauthier, Aline
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S169 - S170
12345